Page last updated: 2024-12-08

1,4,7,10-tetraazacyclododecane-1,7-diacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,4,7,10-tetraazacyclododecane-1,7-diacetic acid, often abbreviated as **DOTA**, is a **macrocyclic chelating agent**. This means it has a large ring structure containing multiple nitrogen atoms capable of binding metal ions.

Here's a breakdown of why DOTA is important for research:

**1. Metal Ion Coordination:**
* DOTA forms very stable complexes with a wide range of metal ions, including gadolinium(III), copper(II), and technetium(I). These complexes are extremely stable, meaning the metal ion is tightly bound and unlikely to dissociate.

**2. Applications in Medicine:**
* **Magnetic Resonance Imaging (MRI):** DOTA is used to create **contrast agents** for MRI. When complexed with gadolinium(III), it forms a compound called **gadolinium DOTA** (Gd-DOTA) which enhances the contrast in MRI images, allowing for better visualization of tissues and organs.
* **Radiopharmaceuticals:** DOTA complexes with radioactive metals like technetium(I) are used in **radiopharmaceutical imaging**. These complexes can target specific organs or tissues in the body, allowing for the detection and diagnosis of diseases.
* **Drug Delivery:** DOTA can be conjugated to drugs or other molecules, allowing for the development of targeted drug delivery systems. This can improve drug efficacy and reduce side effects.
* **Bio-conjugation:** DOTA can be used to attach metal ions to biomolecules like proteins and antibodies, facilitating their detection and manipulation.

**3. Research Uses:**
* **Metal Ion Sensing:** DOTA can be used as a sensor for specific metal ions. When a target metal ion binds to DOTA, it can induce a change in the molecule's fluorescence or other properties, allowing for its detection.
* **Catalysis:** DOTA complexes with metal ions can act as catalysts for various chemical reactions.
* **Material Science:** DOTA can be used to create functional materials with specific properties.

**In summary:** 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid (DOTA) is a versatile and important molecule due to its ability to form stable complexes with metal ions. This property makes it a key component in various applications, ranging from medical imaging to catalysis, and fuels ongoing research in diverse fields.

1,4,7,10-tetraazacyclododecane-1,7-diacetic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID387353
CHEMBL ID1907387
SCHEMBL ID337070
MeSH IDM0561373

Synonyms (10)

Synonym
NCI60_028931
1,4,7,10-tetraazacyclododecane-1,7-diacetic acid
2-[7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
SCHEMBL337070
SPSJFVXUOKRIGT-UHFFFAOYSA-N ,
CHEMBL1907387
112193-75-6
2,2'-(1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetic acid
2-[7-(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid
R6KN864Z5Q
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]